CBDN — Cbd Global Sciences Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Cbd Global Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 2.32 | 0.289 | 0.167 |
| Cost of Revenue | |||
| Gross Profit | -2.73 | -0.061 | 0.041 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 11.4 | 5.59 | 5.37 |
| Operating Profit | -9.07 | -5.3 | -5.2 |
| Net Income Before Taxes | -9.07 | -5.3 | -5.2 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -8.96 | -5.3 | -5.2 |
| Net Income Before Extraordinary Items | |||
| Extraordinary Items | |||
| Net Income | -8.96 | -8.93 | -5.25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -8.96 | -8.93 | -5.25 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.53 | -0.115 | 0.01 |